Doctors Speak Out with Dr. Richard Schlegel
For more than three decades, Richard Schlegel, MD, PhD, has been focused on one goal: decreasing the incidence of cervical cancer, the second leading cause of cancer deaths in women globally. Dr. Schlegel’s prominence in the field of prevention research is based on discoveries that provided the scientific foundation for the first
human papillomavirus (HPV) vaccine. In 2010, the U.S. Food and Drug Administration approved Gardasil to be administered to females to prevent cervical cancer. Today, a new generation of HPV vaccines are given to both males and females that can prevent at least six types of cancer—with the potential to significantly reduce human suffering and deaths around the world.
Dr. Schlegel’s more recent research involving cervical cancer may lead to another important advance by treating women already infected with HPV and a precancerous condition that often leads to the development of cervical cancer. It’s a strategy that uses a novel treatment delivery system with a repurposed anti-malarial drug. Clinical trials with this technique are underway.
In addition to this important work, Dr. Schlegel’s attention is also focused on a revolutionary laboratory technique he and fellow researchers developed that is poised to change the way scientists conduct research, while at the same time significantly advance the field of personalized medicine. Join us for a conversation with Georgetown’s Dr. Schlegel as we explore his many scientific contributions.
Monday, April 30, 2018 at 12:00pm to 2:00pm
Georgetown University Hotel & Conference Center 3800 Reservoir Road, NW, Washington, DC